← Back to headlines
Replimune stock surges after FDA advisers back skin cancer drug
Shares of Replimune surged significantly after FDA advisers provided a positive recommendation for the company's skin cancer drug.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
